跳转至内容
Merck
CN
  • Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia.

Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia.

The Journal of experimental medicine (2020-01-31)
Juan Tang, Sha Tu, Guoxin Lin, Hui Guo, Chengkai Yan, Qingjun Liu, Ling Huang, Na Tang, Yizhi Xiao, R Marshall Pope, Murugesan V S Rajaram, Amal O Amer, Brian M Ahmer, John S Gunn, Daniel J Wozniak, Lijian Tao, Vincenzo Coppola, Liwen Zhang, Wallace Y Langdon, Jordi B Torrelles, Stanley Lipkowitz, Jian Zhang
摘要

Aberrant NLRP3 inflammasome activation contributes to the development of endotoxemia. The importance of negative regulation of NLRP3 inflammasomes remains poorly understood. Here, we show that the E3 ubiquitin ligase Cbl-b is essential for preventing endotoxemia induced by a sub-lethal dose of LPS via a caspase-11/NLRP3-dependent manner. Further studies show that NLRP3 undergoes both K63- and K48-linked polyubiquitination. Cbl-b binds to the K63-ubiquitin chains attached to the NLRP3 leucine-rich repeat domain (LRR) via its ubiquitin-associated region (UBA) and then targets NLRP3 at K496 for K48-linked ubiquitination and proteasome-mediated degradation. We also identify RNF125 as an additional E3 ubiquitin ligase that initiates K63-linked ubiquitination of the NLRP3 LRR domain. Therefore, NLRP3 is sequentially ubiquitinated by K63- and K48-linked ubiquitination, thus keeping the NLRP3 inflammasomes in check and restraining endotoxemia.

材料
货号
品牌
产品描述

Sigma-Aldrich
单克隆抗-FLAG® M2 小鼠抗, clone M2, purified immunoglobulin (Purified IgG1 subclass), buffered aqueous solution (10 mM sodium phosphate, 150 mM NaCl, pH 7.4, containing 0.02% sodium azide)
Sigma-Aldrich
单克隆抗 β-肌动蛋白抗体 小鼠抗, clone AC-74, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
单克隆抗-FLAG®, clone SIG1-25, ascites fluid
Sigma-Aldrich
抗-泛素抗体,抗体P4D1-A11, clone P4D1-A11, Upstate®, from mouse
Supelco
烯丙酰草胺, PESTANAL®, analytical standard
Sigma-Aldrich
MISSION® esiRNA, targeting human CBLB